Roche to advance prasinezumab into Phase III development for early-stage Parkinson’s disease
Results from Phase IIb PADOVA and longer term follow-up data suggest clinical…
EHA 2025 | Multiple Studies Report Encouraging Data of Olverembatinib in Ph+ ALL
ROCKVILLE, Md. and SUZHOU, China, June 15, 2025 (GLOBE NEWSWIRE) -- Ascentage…
Pierre Fabre Laboratories Strengthen R&D Portfolio and Announce the Acquisition of the Worldwide Rights for PFL-721 and PFL-241
PFL-721 and PFL-241 are mutant-specific EGFR inhibitors with best-in-class potential, being developed…
[Ad hoc announcement pursuant to Art. 53 LR] Roche provides safety update on Elevidys gene therapy for Duchenne muscular dystrophy in non-ambulatory patients
After a thorough clinical review, the benefit-risk for the use of Elevidys…
Sharecare introduces new interactive solutions to elevate health literacy and increase condition-specific treatment adherence
Utilizing augmented reality, artificial intelligence, and time-based visualization, Sharecare’s newest innovative tools…
Chromafora Receives Frost & Sullivan’s 2025 Global New Product Innovation Award for Excellence in PFAS Water Treatment Solutions
Recognized for its proprietary SELPAXT™ technology, Chromafora is setting a new standard…
European Commission Approves Duvyzat for the Treatment of Duchenne Muscular Dystrophy
MILAN, Italy, June 06, 2025 – Italfarmaco S.p.A. announced today that the…
ImPact Biotech Announces Treatment of First Patient in Phase 1 Clinical Trial of Padeliporfin VTP in Locally Advanced Unresectable Pancreatic Ductal Adenocarcinoma (PDAC)
June 05, 2025 16:31 ET | Source: ImPact Biotech – Previously inoperable…
HUTCHMED and Innovent Jointly Announce NDA Acceptance in China for Fruquintinib Combination with Sintilimab for the Treatment of Advanced Renal Cell Carcinoma
HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 05, 2025 (GLOBE…
ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy
VIENNA, June 5, 2025 /PRNewswire/ -- New 100-week data from the ongoing…